Drug Profile
Gamma delta T-cell immunotherapy - Beijing Doing Biomedical
Alternative Names: γδ T-cell immunotherapyLatest Information Update: 28 Dec 2019
Price :
$50
*
At a glance
- Originator Beijing Doing Biomedical
- Class Antineoplastics; Cell therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Gastric cancer
Most Recent Events
- 28 Dec 2019 No recent reports of development identified for preclinical development in Gastric-cancer in China (Parenteral)
- 30 Nov 2015 Preclinical trials in Gastric cancer in China (unspecified route)
- 30 Nov 2015 Beijing Doing Biomedical plans a phase I/II trial for Gastric cancer (Late-stage disease) in China (NCT02585908)